Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma

Summary Background Pazopanib is approved for metastatic renal cell carcinoma (RCC). We assessed the safety and efficacy of pazopanib with a low fat meal (LFM):

Saved in:
Bibliographic Details
Published in:Investigational new drugs 2019-04, Vol.37 (2), p.323-330
Main Authors: Reimers, Melissa A., Shango, Maryann M., Daignault-Newton, Stephanie, Dedinsky, Rachel, Karsies, Danielle, Kraft, Shawna, Riddle, Liam, Felton, Jeremy A., Wen, Bo, Gersch, Christina, Rae, James M., Redman, Bruce G., Alva, Ajjai S.
Format: Article
Language:English
Subjects:
Aged
Angiogenesis Inhibitors - therapeutic use
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - therapy
Clear cell-type renal cell carcinoma
Combined Modality Therapy
Diet, Fat-Restricted - methods
Dosage
Female
Follow-Up Studies
Humans
Indazoles
Inhibitor drugs
Kidney cancer
Kidney Neoplasms - pathology
Kidney Neoplasms - therapy
Low fat
Male
Medicine
Medicine & Public Health
Metastases
Metastasis
Middle Aged
Oncology
Patients
Pharmacology
Pharmacology/Toxicology
Phase II Studies
Polymorphism
Prognosis
Pyrimidines - therapeutic use
Safety
Studies
Sulfonamides - therapeutic use
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Pazopanib is approved for metastatic renal cell carcinoma (RCC). We assessed the safety and efficacy of pazopanib with a low fat meal (LFM):
ISSN:0167-6997
1573-0646
DOI:10.1007/s10637-018-0692-8